Category - News

Developments

Piper resumes coverage of NxStage Medical at overweight

Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday. “We have known the story since...

March 31, 2016

Developments

Oramed gets Indian patent for oral administration of proteins

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the...

March 29, 2016

Developments

HHS ups buprenorphine prescribing to treat opioid addiction

In a speech today, President Obama announced that the Department of Health and Human Services (HHS) has issued a new proposed rule to increase the current patient limit for qualified physicians who prescribe...

March 29, 2016

Markets

HCW starts Kiadis Pharma at buy

H.C. Wainwright has launched coverage of Kiadis Pharma NV (NXT AM:KDS) of Amsterdam with a “buy” rating and price target of €15. The stock closed at €10 on Friday. “We view Kiadis as an innovator in hematopoietic stem...

March 28, 2016

Markets

HCW assumes coverage of Galmed at buy

H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday. Galmed is focused on the development of a...

March 28, 2016

Developments

Dipexium Pharma receives Locilex patent in Japan

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033...

March 28, 2016

Developments

TransEnterix updates SurgiBot FDA submission

TransEnterix (NYSE MKT:TRXC) has received an update from the FDA on the status of the 510(k) submission for its robotics SurgiBot system to improve minimally invasive surgery. The FDA advised the company that it has not...

March 27, 2016

Markets

Piper Jaffray starts Inogen at neutral

Piper Jaffray has initiated coverage of Inogen (NASDAQ:INGN) with a “neutral” rating and price target of $46. The stock closed at $41.07 on Wednesday. “We truly appreciate the unique technology the company has developed...

March 24, 2016

Developments

Avivagen posts positive swine trial results in China

Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing. The trial evaluated OxC...

March 22, 2016

Developments

Can-Fite submits Phase 3 RA trial protocol to EMA

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid...

March 17, 2016

Category - News

Subscribe